Content validity of a mobile application for home monitoring of motor development in premature infants

Validez de contenido de un aplicativo móvil para el seguimiento en casa del desarrollo motor de niños prematuros

Published 2022-12-05


https://doi.org/10.30554/archmed.22.2.4257.2022
Open | Download
HTML (Spanish) XML (Spanish) epub (Spanish) PDF (Spanish) FLIP
Issue
Vol. 22 No. 2 (2022): .
Section
Artículos de Investigación
How to Cite
Beltrán Pabón, M. F., Nivia Rodriguez, L. Y., Molina Cárdenas, D. C., Ballén Gómez, . E. Y., Hastamorir Clavijo, L. D., & Castellanos, . A. L. (2022). Content validity of a mobile application for home monitoring of motor development in premature infants. Archivos De Medicina , 22(2). https://doi.org/10.30554/archmed.22.2.4257.2022
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
DOI

https://doi.org/10.30554/archmed.22.2.4257.2022
Dimensions
PlumX

How to Cite

Beltrán Pabón, M. F., Nivia Rodriguez, L. Y., Molina Cárdenas, D. C., Ballén Gómez, . E. Y., Hastamorir Clavijo, L. D., & Castellanos, . A. L. (2022). Content validity of a mobile application for home monitoring of motor development in premature infants. Archivos De Medicina , 22(2). https://doi.org/10.30554/archmed.22.2.4257.2022

Download Citation

license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

María Fernanda Beltrán Pabón
Fisioterapeuta. Universidad de La Sabana. Campus del Puente del Común Km. 7, Autopista Norte de Bogotá. Chía, Colombia. Chía, Colombia.
https://orcid.org/0000-0002-3172-3573 ORCID
Luz Yojaira Nivia Rodriguez
Fisioterapeuta. Universidad de La Sabana. Chía, Colombia
https://orcid.org/0000-0002-4888-6395 ORCID
Diana Carolina Molina Cárdenas
Fisioterapeuta. Universidad de La Sabana. Chía, Colombia.
https://orcid.org/0000-0003-2997-2025 ORCID
Erika Yohana Ballén Gómez
Fisioterapeuta. Universidad de La Sabana. Chía, Colombia.
https://orcid.org/0000-0003-0139-9482 ORCID
Lizeth Daniela Hastamorir Clavijo
Fisioterapeuta. Universidad de La Sabana. Chía, Colombia.
https://orcid.org/0000-0002-2947-4846 ORCID
Adriana Lucía Castellanos
Magíster en Pedagogía. Profesor asistente facultad de enfermería y rehabilitación. Universidad de la Sabana.
https://orcid.org/0000-0002-0518-1838 ORCID
Show authors biography

María Fernanda Beltrán Pabón,

x

Luz Yojaira Nivia Rodriguez,

x

Diana Carolina Molina Cárdenas,

x

Erika Yohana Ballén Gómez,

x

Lizeth Daniela Hastamorir Clavijo,

x

Adriana Lucía Castellanos,

x

Summary 

Objective: Determine the content validity of the Hospital-Home mobile application for home monitoring by parents of the motor development of premature children. The active participation of parents is fundamental for the acquisition of motor skills demonstrating better results. Methodology: Quantitative study, a validation process is carried out for the content of an application with the expert judgment technique. Results: A general kappa index of 0.739 was obtained for the content of the application, which indicates a substantial concordance between evaluators.

Conclusions: Home follow-up processes require constant feedback for parents, so the Hospital-mobile appHome can be a useful tool based on scientific evidence for parents by providing reliable information and practices about their children’s motor development.

Key words: premature; motor skills, reproducibility of results, medical informatics applications

Article visits 331 | PDF visits 203

Downloads

Download data is not yet available.
  1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in
  2. the World. Asian Pac J Cancer Prev. 2016; 17(S3):43-46. DOI: https://doi.org/10.7314/apjcp.2016.17.s3.43
  3. Espitia-De La Hoz FJ, De León-Ospina D. Evaluación de la Función sexual en mujeres con cáncer de mama,
  4. en el Quindío. Avances En Salud. 2019; 3(2):8-17. DOI: https://doi.org/10.21897/25394622.1754
  5. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, et al. Tamoxifen
  6. for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel
  7. Project P-1 study. J Natl Cancer Inst. 2005; 97(22):1652-62. DOI: https://doi.org/10.1093/jnci/dji372
  8. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer
  9. survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one
  10. of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075.
  11. DOI: https://doi.org/10.1016/S0140-6736(17)33326-3
  12. Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984; 25(2):127-205.
  13. DOI: https://doi.org/10.1016/0163-7258(84)90043-3
  14. Espitia-De La Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of
  15. women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol. 2018; 69(4):249-259.
  16. DOI: http://dx.doi.org/10.18597/rcog.3111
  17. Espitia-De La Hoz FJ, Orozco Gallego H. Abordaje diagnóstico y terapéutico del síndrome genitourinario en
  18. la menopausia; actualización. Rev Med UCR. 2017; 117:67-84. DOI: https://doi.org/10.15517/rmucr.v11i2.34580
  19. Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal
  20. Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
  21. Climacteric. 2018; 21(3):286-91. DOI: https://doi.org/10.1080/13697137.2018.1446930
  22. Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, et al. Genitourinary syndrome of
  23. menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.
  24. Climacteric. 2018; 21(2):167-73. DOI: https://doi.org/10.1080/13697137.2017.1421921
  25. Palacios S, Cancelo MJ. Clinical update on the use of ospemifene in the treatment of severe symptomatic
  26. vulvar and vaginal atrophy. Int J Womens Health. 2016; 8:617-26. DOI: https://doi.org/10.2147/IJWH.S110035
  27. Espitia-De La Hoz FJ, Orozco Gallego H. Evaluación de la eficacia de la combinación de dos terapias estrogénicas locales más un lubricante vaginal, para el control de los síntomas del síndrome genitourinario de
  28. la menopausia. Revista Investigaciones Andina. 2018; 21(38):167-183. DOI: https://doi.org/10.33132/01248146.998
  29. De Aloysio D, Pennacchioni P, Bonino S. Rational use of vaginal promestriene. Ital J Obstet Gynecol. 1995;
  30. :533–538.
  31. Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of promestriene
  32. as topical oestrogen therapy. Gynecological Endocrinology. 2010; 26(9): 644–651.
  33. DOI: http://dx.doi.org/10.3109/09513591003767948
  34. Trinkaus M, Chin S, Wolfman W, et al. Should urogenital atrophy in breast cancer survivors be treated with
  35. topical estrogens? Oncologist. 2008; 13:222-231. DOI: 10.1634/theoncologist.2007-0234
  36. Biglia N, Bounous VE, Sgro LG, D’Alonzo M, Pecchio S, Nappi RE. Genitourinary Syndrome of Menopause
  37. in Breast Cancer Survivors: Are We Facing New and Safe Hopes? Clin Breast Cancer. 2015; 15(6):413-20.
  38. DOI: 10.1016/j.clbc.2015.06.005
  39. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after
  40. breast cancer: is it safe? Eur J Cancer. 2005; 41(17):2673-81. DOI: 10.1016/j.ejca.2005.07.015
  41. Wolff JP, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol diether topically
  42. active on the vaginal mucosa. Maturitas. 1982; 4(4):239-46. DOI: https://doi.org/10.1016/0378-5122(82)90054-8
  43. The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel.
  44. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
  45. ; 1;29(7):767-794. doi: 10.1097/GME.0000000000002028
  46. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly
  47. clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004; 351(15):1548-1563.
  48. DOI: https://doi.org/ 10.1056/NEJMcpc049016
  49. Blümel JE, Binfa L, Cataldo P, Carrasco A, Izaguirre H, Sarrá S. Índice de función sexual femenina: un test
  50. para evaluar la sexualidad de la mujer. Rev Chil Obstet Ginecol. 2004; 69(2):118-125.
  51. DOI: http://dx.doi.org/10.4067/S0717-75262004000200006
  52. Espitia-De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in 12 colombian
  53. cities, 2009-2016. Rev Colomb Obstet Ginecol. 2018; 69 (1):9-21. DOI: http://dx.doi.org /10.18597/rcog.3035
  54. Espitia-De La Hoz FJ. Evaluación de la prevalencia de disfunción sexual en mujeres médicos, del Eje
  55. Cafetero colombiano, en etapa de climaterio. Arch Med (Manizales). 2017; 17(1):70-77.
  56. DOI: https://doi.org/10.30554/archmed.17.1.1897.2017
  57. World Medical Association (WMA). WMA Declaration of Helsinki – Ethical principles for medical research
  58. involving human subjects. Fortaleza: 64th WMA General Assembly. 2013.
  59. Colombia. Ministerio de Salud. Resolución 8430 de 1993 (oc-tubre 4): Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá D.C.: octubre 4 de 1993.
  60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
  61. Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education
  62. Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
  63. (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-3421.
  64. Kabir F, Jahan N, Sultana N, Akter R. Lipid Profile Status In Surgical Menopause. Journal of Bangladesh
  65. Society of Physiologist. 2011; 6(2):127-133. DOI: https://doi.org/10.3329/jbsp.v6i2.9763
  66. Del Pup L. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol
  67. Endocrinol 2012; 28:740–745. DOI: http://dx.doi.org/10.3109/09513590.2011.652717
  68. Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, Singer CF, Seifert M. Vaginal estriol
  69. to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric. 2011; 14(3):339-344.
  70. DOI: 10.3109/13697137.2010.529967
  71. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or
  72. vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol. 2010; 26(6):404-412. DOI: 10.3109/09513591003632258
  73. Melisko ME, Goldman M, Rugo HS. Amelioration of sexual adverse effects in the early breast cancer patient.
  74. J Cancer Surviv. 2010; 4:247–255. DOI: https://doi.org/10.1007/s11764-010-0130-1
  75. Palacios Gil Antunano S, Peralta J, Mujica I, Fernandez Villoria E. Assessing estradiol diether systemic effects
  76. in premenopausal and postmenopausal women. Presented at the 19th National Congress of Gynecology,
  77. –24 October, Oviedo, Spain; 1987.
  78. Romanini C, Villani L, Pasqua M, Gaglione R, Fischetti C, Fornara CF. Traitement prolonge´ de la vaginite
  79. atrophique par promestriene. Resultats et tolerance. Gynecologie 1980; 31:627–631.
  80. Wurch TA, Lumbroso M, Becker JF. Getting evidence of the lack of systemic effect promestriene used at
  81. high doses. Gynecocology 1988; 39:101–103.
  82. Bonneton A, Dechaud H, Fleury MC, Colau JC, Pugeat M. Lack of influence of promestriene vaginally administered on circulating levels of hormones and estrogen dependent hepatic proteins in postmenopausal
  83. women. Gynecocology 1992; 43:45–48.
  84. Vors J, Muller P. Trophicité vaginale et Colpotrophine. Med Gen 1975; 1 November 1.
  85. Campana G, Di Grancesco. Sindrome climaterica: esperienze cliniche con il promestriene [Climacteric
  86. syndrome: clinical experiences using promestriene]. Ann Ostet Ginecol Med Perinat. 1976; 97(3):189-197.
  87. Villani L, Romanini C, Fornara CF, et al. Trophic disorders in gynecology seniors. Clinical aspects, index
  88. vulvar pathology, vaginal and cervical. Action promestriene. Medicine and 3rd Age 1978; 1:315–321.
  89. Sun AJ, Lin SQ, Jing LH, Wang ZY, Ye JL, Zhang Y. Safety of promestriene capsule used in postmenopausal
  90. atrophic vaginitis. Zhonghua Fu Chan Ke Za Zhi. 2009; 44(8):593-596.
  91. Pompei L de Melo, Fernandes CE, Melo NR. Promestrieno no tratamento da atrofia vulvovaginal: revisão
  92. sistemática / Promestriene for treatment of vulvovaginal atrophy: a systematic review. Femina. 2010;
  93. (7):359-365.

Information

Keywords

QR code

Sistema OJS 3.4.0.10 - Metabiblioteca |